Skip to content

Injectable Depot Formulations — PLGA Microspheres, In Situ Forming Depots, and Hydrogel-Based Long-Acting Peptide Delivery

Executive Summary

Injectable depot formulations represent the most clinically successful platform for long-acting peptide delivery, with a portfolio of approved products spanning decades of clinical use. By converting peptides that would otherwise require daily or multiple-daily injections into formulations requiring administration every week, month, or even several months, these technologies have transformed the treatment of hormone-sensitive cancers, metabolic disorders, and chronic endocrine conditions. The commercial success of products including Lupron Depot® (leuprolide acetate PLGA microspheres, monthly and 3-, 4-, and 6-month formulations), Sandostatin LAR® (octreotide acetate PLGA microspheres, monthly), and Somatuline® Depot (lanreotide, self-assembling nanotube depot, monthly) underscores the clinical and commercial viability of this approach.

This article provides a comprehensive examination of the principal injectable depot technologies for peptide delivery: PLGA microsphere systems (including their degradation kinetics and burst release mechanisms), in situ forming depots (phase separation systems and thermogels), hydrogel-based depots, and oil-based depot formulations. We analyze the critical challenge of maintaining peptide stability within the degrading depot microenvironment, examine the design principles governing release kinetics, review key approved products and their clinical performance, and assess emerging technologies that promise to expand the applicability of depot delivery to a broader range of peptide therapeutics.

Scientific Summary

Injectable depot formulations turn short-lived peptides into week- or month-scale therapies by embedding the drug in a matrix that releases it slowly at the injection site — PLGA microspheres, in situ forming implants, thermogels, hydrogels, oil vehicles, or self-assembling peptide nanostructures. The commercial stakes are high: depot technology defines the modern administration of LHRH agonists, somatostatin analogs, and once-weekly exenatide, so it shapes entire therapeutic categories. What is established: PLGA microspheres are the dominant platform with decades of clinical use; release is typically triphasic (burst, diffusion, erosion); and the acidic microclimate inside degrading PLGA (pH 1.5–3.0) is a genuine chemical stress that must be mitigated rather than ignored. What remains uncertain: achieving zero-order release, trimming burst beyond incremental gains, preserving peptide integrity over multi-month residence, and scaling sterile polymer manufacturing reproducibly.

Evidence Overview

Evidence type What exists — and what does not
Human studies Established for older products — leuprolide, octreotide, lanreotide, triptorelin, goserelin, pasireotide, and exenatide depots carry clinical trial experience; newer depot platforms remain largely untested in humans.
Animal studies Extensive — rodent, rabbit, and non-human primate models underpin most developmental depot platforms; animal release profiles commonly overestimate human performance.
In vitro Primary mechanistic evidence — release testing, degradation studies, and microclimate pH measurements define platform behavior before any animal or human work.
Mechanistic Well characterized — polymer hydrolysis, phase separation, gelation, and diffusion–erosion interplay are understood well enough to support rational design.
Preclinical Broad but stage-limited — most published depot work stops at preclinical validation; translation to approved products is the exception rather than the rule.
Review literature Extensive — two decades of reviews document platforms and lessons; head-to-head comparative studies across platforms are less common.

Background

The Clinical Need for Long-Acting Injectable Peptide Formulations

Many peptide therapeutics face a fundamental pharmacokinetic limitation: short systemic half-lives—typically minutes to hours—due to rapid renal clearance and/or proteolytic degradation. Without formulation intervention, these peptides require frequent injections for chronic therapy. For a peptide with a 2-hour half-life, maintaining therapeutic concentrations with once-daily dosing requires peak-to-trough ratios that may exceed 100:1, with supraphysiological peak concentrations that can drive dose-limiting side effects and subtherapeutic trough concentrations that compromise efficacy.

The clinical consequences of frequent injection regimens extend beyond inconvenience. For LHRH agonists used in prostate cancer and endometriosis, daily injections were the standard of care before the introduction of depot formulations—a burden that significantly impacted treatment adherence and quality of life. For somatostatin analogs used in acromegaly and neuroendocrine tumors, the transition from multiple-daily injections (octreotide immediate-release, t½ ~1.5 hours) to monthly depot administration (Sandostatin LAR®) represented a transformative improvement in the patient experience.

The therapeutic rationale for depot formulations is thus threefold: improved pharmacokinetics (reduced peak-to-trough fluctuation), improved adherence (reduced injection frequency), and—in some cases—improved efficacy (sustained target engagement vs. intermittent exposure).

Historical Development

The concept of sustained-release injectable depots emerged in the 1970s and 1980s with the development of biodegradable polymers for medical applications. Poly(lactic-co-glycolic acid) (PLGA), synthesized by copolymerization of lactic acid and glycolic acid cyclic dimers, was identified as an attractive depot matrix material due to its biodegradability (hydrolytic degradation to metabolizable monomers), biocompatibility (established through extensive toxicological evaluation), and tunable degradation kinetics (through polymer composition, molecular weight, and end-group chemistry).

The first PLGA microsphere depot product, Lupron Depot® (leuprolide acetate for prostate cancer), was approved by the FDA in 1989. This landmark product demonstrated that a peptide requiring daily injection could be formulated for monthly administration while maintaining therapeutic efficacy—and established PLGA microspheres as the gold standard for peptide depot delivery. Subsequent decades saw the approval of additional PLGA-based peptide depots including Sandostatin LAR® (octreotide, 1998), Trelstar® (triptorelin, 2000), and Eligard® (leuprolide, in situ forming depot, 2002).

The self-assembling peptide nanotube technology underlying Somatuline® Depot (lanreotide, approved 2007) represented a fundamentally different approach: rather than a polymeric matrix, the peptide itself assembles into nanotubes that form a depot upon subcutaneous injection, providing sustained release over 28 days through slow dissolution of the assembled structures.

PLGA Microsphere Technology

PLGA microspheres are the most extensively characterized and clinically validated peptide depot platform. The technology involves encapsulating the peptide within spherical PLGA particles typically 10–200 μm in diameter, suspended in an aqueous vehicle for injection. Upon intramuscular or subcutaneous administration, the microspheres form a localized depot from which peptide is released over weeks to months.

Microsphere Fabrication

Double Emulsion (W1/O/W2) Solvent Evaporation: This is the most common method for encapsulating water-soluble peptides. An aqueous peptide solution (internal water phase, W1) is emulsified in an organic PLGA solution (oil phase, O, typically dichloromethane) to form a primary water-in-oil (W1/O) emulsion. This primary emulsion is then emulsified in an aqueous surfactant solution (external water phase, W2, typically containing polyvinyl alcohol) to form a W1/O/W2 double emulsion. Evaporation or extraction of the organic solvent solidifies the polymer, forming microspheres with encapsulated peptide-containing aqueous domains.

The double emulsion method allows high peptide loading (typically 2–15% w/w) but presents complex optimization challenges. The size of internal aqueous droplets (which become the pores within the solidified microspheres) is influenced by the primary emulsification energy and the viscosity and interfacial tension of the two phases. The microsphere size distribution is influenced by the secondary emulsification conditions and the stabilizer concentration. Internal droplet coalescence during solvent evaporation can create large voids that increase burst release and reduce encapsulation efficiency.

Coacervation (Phase Separation): An alternative to solvent evaporation, coacervation involves adding a non-solvent (typically silicone oil) to a PLGA solution containing dispersed peptide particles, inducing phase separation of the polymer into a coacervate phase that encapsulates the peptide. The coacervate droplets are then hardened by transfer to a second non-solvent that extracts the remaining organic solvent. Coacervation can achieve higher encapsulation efficiencies for certain peptides and allows processing of heat-sensitive peptides that might be degraded at the elevated temperatures sometimes used for solvent evaporation. Lupron Depot® is manufactured using a coacervation process.

Spray Drying: Atomization of a peptide-polymer solution or suspension into a heated drying chamber produces microspheres in a single continuous step, offering manufacturing simplicity and scalability. However, the elevated temperatures and air-liquid interfaces can denature certain peptides, and the resulting microspheres may have higher porosity (and burst release) than those produced by emulsion methods.

Sterile Manufacturing Considerations: Terminal sterilization of PLGA microspheres by gamma irradiation can degrade both the polymer (reducing molecular weight and accelerating release) and the peptide (through free radical-mediated oxidation). Consequently, PLGA microsphere products are typically manufactured aseptically, adding substantial complexity and cost. Low-temperature ethylene oxide sterilization has been used for some products but raises concerns about residual ethylene oxide and its reaction products.

PLGA Degradation Kinetics

PLGA degrades through bulk hydrolysis of ester bonds in the polymer backbone. Water diffuses into the polymer matrix faster than the degradation products diffuse out, resulting in homogeneous degradation throughout the microsphere (bulk erosion) rather than surface-limited degradation (surface erosion).

The degradation process proceeds through several phases. In the initial hydration phase (hours to days), water penetrates the polymer matrix, plasticizing it and initiating ester bond hydrolysis. The molecular weight begins to decrease while mass loss is minimal. In the latent degradation phase (days to weeks, depending on polymer composition), random chain scission continues, progressively reducing the molecular weight. The glass transition temperature (Tg) of the hydrated polymer decreases as the molecular weight falls. When the molecular weight reaches a critical threshold (~5,000–10,000 Da) below which the degradation products become sufficiently water-soluble to diffuse out, the erosion phase begins with measurable mass loss. In the terminal phase, the polymer matrix completely disintegrates, releasing any remaining encapsulated peptide.

The degradation rate is primarily determined by the lactic-to-glycolic acid (L:G) ratio. Poly(glycolic acid) degrades in approximately 1–2 months; 50:50 PLGA degrades in approximately 1–2 months; 75:25 PLGA degrades in approximately 4–5 months; 85:15 PLGA degrades in approximately 5–6 months; and poly(L-lactic acid) degrades in >24 months. The difference arises from the methyl side group of lactic acid, which sterically hinders ester bond hydrolysis. Higher glycolide content also increases hydrophilicity, accelerating water uptake.

Polymer molecular weight is the second major determinant: lower molecular weight polymers degrade more rapidly because fewer chain scission events are required to reach the critical molecular weight for erosion. End-group chemistry (free carboxylic acid vs. ester-capped) moderately influences degradation rate, with carboxylic acid end groups autocatalyzing hydrolysis.

Burst Release

Burst release—the rapid release of a substantial fraction of the encapsulated peptide within the first 24 hours after injection—is a nearly universal phenomenon with PLGA microspheres and a critical quality attribute for depot products. Burst release typically ranges from 5–30% of the total dose and arises from peptide located on or near the microsphere surface that is immediately accessible to the release medium.

Burst release is influenced by multiple formulation and process parameters. Higher peptide loading increases burst release by increasing the fraction of peptide near the surface. Larger internal pores (resulting from coalescence of internal aqueous droplets during fabrication) increase burst release by providing direct diffusion pathways to the surface. Incomplete solvent removal can leave a more porous, permeable surface layer. Peptide migration to the microsphere surface during the drying step (driven by convective solvent flow) enriches the surface peptide concentration.

The clinical implications of burst release depend on the peptide's therapeutic index. For peptides with wide therapeutic indices (LHRH agonists, for which an initial "flare" of gonadotropin stimulation is an expected and clinically managed phenomenon), burst release may be acceptable or even therapeutically exploited. For peptides with narrow therapeutic indices, excessive burst release can cause dose-limiting toxicity. Managing burst release—through formulation strategies including surface extraction (washing microspheres to remove surface peptide), coating with a drug-free polymer layer, or incorporating peptide as a poorly soluble salt that dissolves slowly—is a central challenge in microsphere formulation development.

Peptide Stability in PLGA Microspheres

The stability of peptides within degrading PLGA microspheres is perhaps the most critical and challenging aspect of depot formulation. The acidic microclimate generated by PLGA degradation (internal pH 1.5–3.0) can catalyze multiple peptide degradation pathways:

Deamidation: Asparagine residues are particularly susceptible to acid-catalyzed deamidation, forming aspartic acid and isoaspartate through a cyclic imide intermediate. Deamidation can alter peptide charge, conformation, and biological activity.

Oxidation: Methionine and cysteine residues are susceptible to oxidation in the microenvironment of degrading PLGA, potentially driven by reactive oxygen species generated through polymer degradation or residual peroxides from PLGA synthesis.

Acylation: The reaction of peptide amino groups (N-terminus, lysine side chains) with PLGA or its degradation products (lactic and glycolic acid oligomers) can form amide adducts that alter peptide structure and activity. Acylation is favored in the low-pH, high-concentration environment within the microsphere.

Aggregation: The high effective peptide concentration within the microsphere aqueous domains, combined with pH changes and potential conformational destabilization, can promote peptide aggregation—particularly for peptides with aggregation-prone sequences containing hydrophobic or β-sheet-forming regions.

Strategies for Peptide Stabilization:

Several formulation strategies can mitigate peptide degradation in PLGA depots. Co-encapsulation of poorly soluble basic salts (magnesium hydroxide, zinc carbonate, calcium carbonate) that dissolve slowly and buffer the microclimate pH to near-neutral values has demonstrated significant stabilization effects for acid-labile peptides. The use of PLGA with higher lactide content (slower degradation, slower acid generation) or lower molecular weight (faster diffusion of acidic products out of the matrix) can reduce peak acidity. Formulating the peptide as a poorly soluble salt (pamoate, stearate) or complex (zinc complex) reduces the dissolved peptide concentration susceptible to degradation. And incorporating antioxidants (ascorbic acid, tocopherol, methionine as a sacrificial oxidant) can protect against oxidation.

In Situ Forming Depots

In situ forming depots are injectable liquid formulations that solidify or precipitate upon contact with the physiological environment to form a solid or semi-solid implant at the injection site. This approach eliminates the manufacturing complexity of pre-formed microspheres and allows administration through a standard needle (typically 18–23 gauge), but introduces new challenges related to the reproducibility of the in situ solidification process and the resulting release kinetics.

Phase Separation (Atrigel®) Systems

The Atrigel® technology, commercialized in Eligard® (leuprolide acetate) and several other products, is based on the phase separation of a water-insoluble biodegradable polymer from a water-miscible organic solvent upon contact with aqueous physiological fluids. The system consists of PLGA (or other biodegradable polymer) and the peptide dissolved or dispersed in a biocompatible organic solvent—most commonly N-methyl-2-pyrrolidone (NMP). Upon injection into the subcutaneous or intramuscular space, the water-miscible solvent diffuses out of the formulation while water diffuses in. As the solvent concentration decreases below the polymer solubility limit, PLGA precipitates to form a solid implant with entrapped peptide.

Release Kinetics and Controlling Factors: The release kinetics from Atrigel® implants are governed by the complex interplay of solvent exchange, phase separation dynamics, implant morphology, polymer degradation, and peptide diffusion. The high initial solvent concentration and the phase separation kinetics produce an implant with a porous, interconnected structure that can result in high initial burst release (often 10–50% in the first 24 hours). As the implant matures (loss of residual solvent, polymer chain relaxation), the release rate typically decreases, entering a diffusion-controlled phase followed by an erosion-accelerated terminal phase as the polymer degrades.

The burst release and overall release rate are influenced by the polymer concentration (higher polymer = denser implant = lower burst), the polymer molecular weight and composition, the solvent type (NMP diffuses more rapidly than dimethyl sulfoxide (DMSO), dimethyl acetamide, or triacetin, producing different implant morphologies), the peptide loading, and the injection site (vascularity affecting solvent removal rate).

Peptide Stability Considerations: The organic solvent exposure during formulation preparation and the initial post-injection period can compromise peptide stability. NMP, while biocompatible at the doses used, can denature certain peptides if direct contact occurs. The peptide is typically dispersed as solid particles rather than dissolved in the solvent to minimize solvent exposure, but dissolution of a fraction of the particles in the solvent can lead to degradation. The solvent concentration gradient during the phase separation and implant hardening period can produce local solvent concentrations at the implant-tissue interface that cause tissue irritation, manifesting as injection site pain or inflammation.

Thermogels (Thermoresponsive Hydrogels)

Thermogel systems are aqueous polymer solutions that undergo a sol-to-gel transition upon warming from room temperature to body temperature, forming a hydrogel depot at the injection site. This approach avoids organic solvents entirely, eliminating solvent-related peptide stability and tissue irritation concerns.

Poloxamer (Pluronic®) Thermogels: Poloxamer 407 (Pluronic® F127) is a triblock copolymer of poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) (PEO-PPO-PEO) that forms micelles at low temperatures and undergoes micelle packing/ordering into a gel network at body temperature at concentrations above approximately 15–20% w/w. Poloxamer thermogels are easy to prepare, well-tolerated, and have been extensively studied for peptide delivery. However, poloxamer gels are physically crosslinked (non-covalent) and dissolve relatively rapidly (typically hours to 1–2 days), limiting their utility to relatively short-duration depot applications unless chemically modified for slower dissolution.

PLGA-PEG-PLGA Triblock Copolymers (ReGel®): PLGA-PEG-PLGA triblock copolymers, developed by MacroMed (now BTG), undergo reversible thermogelation through a mechanism involving micelle formation and micelle aggregation. Below the critical gelation temperature, the copolymer exists as individual micelles in a free-flowing sol. As the temperature increases to body temperature, the micelles aggregate into a percolated network that constitutes a physical gel. The PLGA block length and lactide-to-glycolide ratio control the gelation temperature, gel strength, and degradation/resorption rate.

The ReGel® system (trademarked ReGel®) has been evaluated for sustained peptide delivery including GLP-1 agonists, LHRH agonists, and growth hormone. The aqueous processing conditions are favorable for peptide stability, and the PLGA-PEG-PLGA gel degrades and is resorbed over weeks to months with tunable kinetics.

PNIPAM-Based Thermogels: Poly(N-isopropylacrylamide) (PNIPAM) exhibits a sharp lower critical solution temperature (LCST) at approximately 32°C in water; below this temperature, PNIPAM is water-soluble; above this temperature, it undergoes a coil-to-globule transition and precipitates. PNIPAM copolymers and hydrogels can be engineered with LCST near physiological temperature for injectable depot applications. However, the non-biodegradability of the PNIPAM backbone raises concerns for depot applications requiring complete resorption, motivating the development of biodegradable PNIPAM analogs and copolymers.

In Situ Crosslinking Systems

Injectable formulations that crosslink (chemically or physically) upon injection offer mechanical robustness and tunable degradation through crosslink density control. Chemical crosslinking systems employ reactive groups that form covalent bonds under physiological conditions—for example, Michael addition of thiols to acrylates or maleimides, or hydrazone formation between hydrazides and aldehydes. Physical crosslinking systems employ non-covalent interactions including ionic interactions (e.g., alginate with calcium), hydrophobic interactions, or stereocomplexation (e.g., enantiomeric polylactic acid blocks).

The challenge for in situ crosslinking systems is achieving sufficiently rapid and complete crosslinking at the injection site without premature crosslinking in the syringe (requiring dual-barrel syringe systems or careful kinetic control), and ensuring that the crosslinking chemistry and reaction byproducts are compatible with peptide stability and tissue biocompatibility.

Hydrogel Depot Systems

Hydrogels are three-dimensional, water-swollen polymer networks that can serve as peptide depot matrices. Unlike PLGA microspheres, hydrogels maintain a hydrated environment that can be favorable for peptide conformational stability.

Synthetic Hydrogels

PEG-Based Hydrogels: PEG hydrogels are formed from multi-arm PEG macromolecules terminated with reactive groups for crosslinking. Michael addition of thiol-terminated PEG to acrylate or maleimide-terminated PEG proceeds rapidly under physiological pH and temperature conditions, enabling in situ gelation. PEG hydrogels are intrinsically resistant to protein adsorption and cell adhesion, reducing the foreign body response that can alter release kinetics. The crosslink density, degradation rate (through incorporation of hydrolytically or enzymatically cleavable linkers), and mesh size can be precisely engineered to control peptide release.

Poly(vinyl alcohol) (PVA) Hydrogels: PVA hydrogels, typically crosslinked by freeze-thaw cycling (physical crosslinking through crystallization) or chemical crosslinking (glutaraldehyde, though this is problematic for in vivo applications), offer high water content, mechanical toughness, and long-term stability. PVA hydrogels have been investigated for sustained peptide delivery but are limited by the harsh crosslinking conditions that are incompatible with peptide co-formulation.

Natural and Semi-Synthetic Hydrogels

Hyaluronic Acid (HA) Hydrogels: HA is a naturally occurring glycosaminoglycan that is biodegradable, biocompatible, and intrinsically bioactive (CD44 receptor binding, involvement in cell signaling). Chemical modification of HA with thiol, methacrylate, or hydrazide groups enables in situ crosslinking under physiological conditions. HA hydrogels have been investigated for local peptide delivery in applications including wound healing, tissue engineering, and oncology.

Alginate Hydrogels: Alginate gels in the presence of divalent cations (particularly calcium) through ionic crosslinking of guluronic acid blocks. The mild gelation conditions are favorable for peptide stability, and the gelation rate can be controlled by using insoluble calcium salts (calcium sulfate, calcium carbonate) with controlled dissolution rates (internal gelation) rather than soluble calcium chloride (which causes instantaneous, inhomogeneous gelation). Alginate hydrogels degrade through ion exchange (calcium for monovalent cations), dissolution, and, for chemically modified alginates, hydrolytic or enzymatic cleavage.

Collagen and Gelatin Hydrogels: Collagen forms physically crosslinked hydrogels at physiological temperature and pH, providing a bioactive matrix that can promote tissue integration. Gelatin (denatured collagen) forms thermoreversible physical gels and can be chemically crosslinked for enhanced stability. The bioactivity (cell adhesion domains, enzymatic degradability) can be advantageous for tissue engineering applications but may result in variable degradation rates depending on the local tissue environment.

Self-Assembling Peptide Hydrogels: Short peptides designed to self-assemble into β-sheet-rich nanofibers that entangle into hydrogel networks represent a peptide-centric depot approach. The self-assembling peptide RAD16-I (commercially available as PuraMatrix®) and related sequences have been investigated for sustained peptide delivery including growth factors and peptide hormones. The aqueous, mild self-assembly conditions and the peptide-based matrix chemistry are inherently compatible with peptide cargo.

Oil-Based Depot Formulations

Oil-based depots, in which the peptide is suspended as solid particles or dissolved as a lipophilic conjugate in a biocompatible oil, represent a simple and established depot technology. The oil vehicle serves as a diffusion barrier, with peptide release governed by partitioning of dissolved peptide from the oil into the surrounding aqueous tissue fluid.

Oil Vehicles: Sesame oil, castor oil, peanut oil, and medium-chain triglycerides have been used in injectable depot products. Sesame oil is the vehicle for several steroid hormone depot injections (testosterone enanthate, estradiol valerate) and has an extensive safety record. The oil viscosity influences the initial dispersion of the depot and the rate of peptide dissolution: higher viscosity oils slow peptide release but may be more difficult to inject through standard-gauge needles.

Peptide Modification for Oil Solubility: Therapeutic peptides are generally water-soluble and poorly soluble in oils. Converting the peptide to a lipophilic salt or complex—for example, peptide pamoate, peptide stearate, or peptide-zinc complex—can increase oil dispersibility. Alternatively, covalent conjugation with lipophilic moieties (fatty acids, cholesterol) can create oil-soluble peptide prodrugs that slowly partition into the aqueous phase, where the conjugate is hydrolyzed to release the active peptide.

Advantages and Limitations: Oil-based depots are simple to manufacture (mixing/milling of peptide in oil vehicle), avoid the peptide stability challenges associated with PLGA degradation, and have an established regulatory framework through decades of use for steroid hormone products. However, oil-based depots typically provide shorter release durations (days to 2–4 weeks) than PLGA microspheres (1–6 months), are limited to peptides that can be formulated with adequate oil dispersibility, and may cause injection site reactions (oil granulomas, sterile abscesses) that are typically mild but can affect patient acceptance.

Approved Injectable Depot Peptide Products

The table below summarizes key approved injectable depot peptide products, their technologies, and their dosing schedules:

Product (Brand) Peptide Depot Technology Dosing Interval Indication Initial Approval
Lupron Depot® Leuprolide acetate PLGA microspheres (coacervation) 1, 3, 4, or 6 months Prostate cancer, endometriosis, uterine fibroids, central precocious puberty 1989 (FDA)
Sandostatin LAR® Octreotide acetate PLGA microspheres (emulsion) 28 days Acromegaly, neuroendocrine tumors, carcinoid syndrome 1998 (FDA)
Somatuline® Depot Lanreotide acetate Self-assembling peptide nanotube 28 days Acromegaly, neuroendocrine tumors 2007 (FDA)
Trelstar® Triptorelin pamoate PLGA microspheres 1, 3, or 6 months Prostate cancer 2000 (FDA)
Eligard® Leuprolide acetate In situ forming depot (Atrigel®, PLGA/NMP) 1, 3, 4, or 6 months Prostate cancer 2002 (FDA)
Zoladex® Goserelin acetate PLGA solid implant (pre-formed) 1 or 3 months Prostate cancer, breast cancer, endometriosis 1989 (FDA)
Signifor® LAR Pasireotide pamoate PLGA microspheres 28 days Acromegaly, Cushing's disease 2014 (FDA)
Bydureon®/Bydureon BCise® Exenatide PLGA microspheres 7 days Type 2 diabetes 2012 (FDA)

Research Evidence

Depot Technology Peptide Study Design Key Finding Reference
PLGA microspheres (Lupron Depot) Leuprolide Phase III (approved) Sustained testosterone suppression to castrate levels over 1–6 months Sharifi R, et al. J Urol. 1990
PLGA microspheres (Sandostatin LAR) Octreotide Phase III (approved) Sustained IGF-1 and GH suppression; non-inferior to SC octreotide TID Lancranjan I, et al. Metabolism. 1996
Self-assembling nanotube (Somatuline Depot) Lanreotide Phase III (approved) Sustained GH/IGF-1 suppression over 28 days; patient preference for monthly injection Caron P, et al. Clin Endocrinol. 2004
Atrigel in situ depot (Eligard) Leuprolide Phase III (approved) Testosterone suppression equivalent to Lupron Depot; reduced injection volume Perez-Marreno R, et al. Urology. 2002
Mg(OH)₂-co-encapsulated PLGA MS Octreotide Preclinical (rat) Reduced acylation; 2× peptide stability vs. standard PLGA MS Schwendeman SP, et al. J Control Release. 2002
PLGA-PEG-PLGA thermogel (ReGel) Insulin Preclinical (rat) Sustained glucose reduction over 7–14 days from single injection Zentner GM, et al. J Control Release. 2001
PEG hydrogel (in situ crosslinked) GLP-1 analog Preclinical (mouse) Sustained glycemic control over 14 days; tunable release via crosslink density Vermonden T, et al. Chem Rev. 2012
Oil-based depot (sesame oil) Exenatide-lipid conjugate Preclinical (rat) Sustained plasma levels over 7 days; reduced injection frequency Pechenov S, et al. J Control Release. 2019
HA-tyramine hydrogel depot Interferon alpha-2a Preclinical (mouse) Sustained antiviral activity over 7 days; reduced systemic toxicity Xu K, et al. Biomacromolecules. 2012
PLGA microspheres with zinc carbonate rhGH Preclinical (monkey) Reduced aggregation; sustained hGH levels over 30 days Johnson OL, et al. Nat Med. 1996
Alginate-chitosan in situ gel Calcitonin Preclinical (rat) Sustained hypocalcemic effect over 14 days Liu L, et al. Int J Pharm. 2006
PLGA microspheres (Bydureon) Exenatide Phase III (approved) Sustained plasma exenatide over 7 days; HbA1c reduction; once-weekly dosing Drucker DJ, et al. Lancet. 2008

Current Understanding

The current landscape of injectable depot peptide formulations reflects a mature technology platform with well-established clinical proof-of-concept and a significant pipeline of next-generation products. Several key themes characterize current understanding:

PLGA microspheres are the dominant platform but are not without limitations. The extensive clinical experience, established manufacturing infrastructure, and regulatory precedent make PLGA microspheres the default choice for peptide depot development. However, the complexity of microsphere manufacturing, the challenge of peptide stability in the acidic degradation microenvironment, the inherent burst release, and the difficulty of achieving zero-order (constant-rate) release kinetics remain significant limitations.

In situ forming depots offer manufacturing simplicity at the cost of reproducibility challenges. The Atrigel® system and related technologies eliminate the complex microsphere manufacturing steps, but the in situ solidification process is sensitive to local tissue conditions (vascularity, fluid volume, temperature) that can vary between injection sites and between patients, resulting in variable release kinetics.

Peptide stability within the depot remains the central formulation challenge. The physical and chemical stresses within degrading PLGA depots—acidic pH, high effective peptide concentration, reactive degradation products—constitute a harsh environment that many peptides cannot survive for the intended depot duration. Peptide stabilization strategies, particularly pH modulation through co-encapsulated basic excipients, have demonstrated promise but are peptide-specific and require empirical optimization.

Manufacturing at scale is the commercialization bottleneck. Sterile, reproducible manufacturing of PLGA microspheres at commercial scale is a significant challenge that has limited the number of approved products despite decades of research. The capital investment, specialized equipment, and process development expertise required create significant barriers to entry. Continuous manufacturing approaches and intensified process analytical technology (PAT) are being developed to address these barriers.

Self-assembling peptide depots offer a paradigm shift. The success of Somatuline® Depot (lanreotide, self-assembling nanotubes) demonstrates that peptide depot delivery need not rely on a polymeric matrix. Peptides that self-assemble into nanostructures with appropriate dissolution kinetics can function as their own depot, eliminating carrier-related manufacturing complexity and stability concerns.

Future Research Directions

  • Zero-order release PLGA systems that achieve constant-rate peptide delivery through innovative microsphere architectures (core-shell, multi-layer, gradient composition) and through microsphere size fractionation and blending strategies

  • Peptide stabilization through molecular engineering including prodrug strategies that convert chemically labile residues to stable prodrug forms that regenerate the active peptide upon release

  • Continuous, aseptic microsphere manufacturing based on membrane emulsification, microfluidics, or in-line solvent extraction that reduces batch-to-batch variability and manufacturing cost

  • Expanded self-assembling peptide depot systems identifying peptide sequences and assembly conditions that produce depot structures with tunable dissolution kinetics across a range of therapeutic peptides

  • Multi-peptide depot formulations that co-encapsulate peptide combinations for synergistic therapy in a single injection, with independently tunable release kinetics for each component

  • Responsive depot systems that modulate peptide release in response to physiological signals—glucose-responsive insulin depots, inflammation-responsive anti-inflammatory peptide depots—to approximate physiological feedback control

  • In silico depot design and optimization through multi-physics computational models integrating polymer degradation kinetics, peptide diffusion, pH evolution, and in vivo transport to predict release profiles and guide formulation optimization

  • Depot imaging and monitoring through incorporation of imaging contrast agents or reporter systems that enable non-invasive monitoring of depot status, peptide release, and tissue response

  • Ultrasonography-guided or X-ray-visible depots that allow clinicians to confirm proper depot placement, detect depot migration, and monitor depot resorption

  • Longer-acting depots (6–12 months) for chronic peptide therapies where extended dosing intervals could substantially improve patient adherence and quality of life

Frequently Asked Questions

How do PLGA microspheres release peptides over weeks to months?

PLGA microspheres release encapsulated peptides through a combination of mechanisms that evolve over time. In the first 24 hours, "burst release" occurs from peptide located on or near the microsphere surface—typically 5–30% of the total dose. After the burst, release enters a diffusion-controlled phase: water penetrates into the microsphere, dissolves entrapped peptide, and the dissolved peptide diffuses out through the polymer matrix and water-filled pores. This phase typically produces a slowly declining release rate as the diffusion path length increases. As the PLGA degrades through ester bond hydrolysis, the polymer molecular weight decreases until the degradation products become water-soluble enough to diffuse out, at which point the polymer matrix begins to erode. This erosion phase can accelerate release in the terminal period. The overall profile is usually triphasic: burst → diffusion-controlled decline → erosion-accelerated terminal release. The polymer composition (lactide:glycolide ratio), molecular weight, and end-group chemistry determine the timing and relative contributions of each phase.

What causes burst release and how can it be minimized?

Burst release arises from peptide located on or within a few micrometers of the microsphere surface that dissolves immediately upon contact with tissue fluid. Factors increasing burst release include high peptide loading (more peptide near the surface), large internal pores that create direct diffusion pathways from the interior to the surface, peptide migration to the surface during the drying step (convective flow driven by solvent evaporation), and residual solvent creating a porous surface layer. Strategies to minimize burst release include: washing microspheres with a solvent that extracts surface peptide without dissolving the polymer; coating microspheres with a thin, drug-free polymer layer to seal surface pores; formulating the peptide as a poorly soluble salt or complex that dissolves slowly; optimizing the drying process to minimize peptide surface migration; and using higher polymer concentration or higher molecular weight polymer that forms a denser, less permeable matrix. In some applications, burst release is clinically exploited—the LHRH agonist "flare" effect, where initial gonadotropin stimulation precedes suppression, is an expected physiological response to the initial burst.

How does the Atrigel® in situ forming depot system differ from PLGA microspheres?

The Atrigel® system (used in Eligard®) consists of PLGA dissolved in the biocompatible organic solvent N-methyl-2-pyrrolidone (NMP), with the peptide dispersed as solid particles. Upon injection, NMP diffuses out while water diffuses in, causing PLGA to precipitate into a solid implant at the injection site. Key differences from pre-formed microspheres: Atrigel® is manufactured as a liquid solution/dispersion, eliminating the complex microsphere fabrication, washing, drying, and sizing steps. The in situ implant typically has higher initial burst release (often higher and more variable) because phase separation produces a porous structure. The organic solvent (NMP) can cause transient injection site pain and potential peptide stability concerns from solvent exposure. The solidification process is sensitive to local tissue conditions, potentially producing variable release kinetics. The liquid formulation is simpler to administer (standard syringe and needle vs. microsphere suspension requiring specialized needles and reconstitution), and dose flexibility is greater since the same formulation can deliver different volumes.

How does the acidic microenvironment inside degrading PLGA depots affect peptides?

As PLGA degrades through ester bond hydrolysis, lactic and glycolic acids accumulate within the microsphere or implant interior. Because these acidic products diffuse out more slowly than they are generated (particularly in larger particles), the internal pH can drop to 1.5–3.0. This acidic microenvironment catalyzes several peptide degradation pathways: deamidation of asparagine and glutamine residues (altering charge and potentially activity), acid-catalyzed peptide bond hydrolysis at labile sequences (particularly Asp-X bonds), and acylation of peptide amine groups by PLGA oligomers (forming covalent peptide-impurity adducts). The extent of degradation is peptide-specific and depends on the peptide's acid lability, the duration of exposure (determined by the depot's degradation rate), and the internal pH profile. Mitigation strategies include co-encapsulation of basic salts (Mg(OH)₂, ZnCO₃) to buffer the microclimate and selection of slower-degrading PLGA compositions. For researchers studying peptide stability under depot-relevant conditions, analytical reference materials with documented stability characteristics are available through [RPL Peptide](https://rplpeptides.com).

What is the difference between physical and chemical hydrogels for depot delivery?

Physical hydrogels are crosslinked by non-covalent interactions: ionic interactions (alginate + Ca²⁺), hydrophobic interactions (Pluronic thermogels), hydrogen bonding, stereocomplexation, or chain entanglement. They are inherently reversible (can dissolve/disperse when the crosslinking interaction is disrupted), typically have lower mechanical strength, and generally degrade/resorb more rapidly than chemical hydrogels. Chemical hydrogels are crosslinked by covalent bonds (Michael addition, hydrazone formation, enzymatic crosslinking, photopolymerization). They are irreversible (cannot be dissolved without bond cleavage), offer higher mechanical strength, more precise control over mesh size and degradation rate through crosslink density, and can be engineered with hydrolytically or enzymatically cleavable crosslinks for controlled resorption. For peptide depot applications, physical hydrogels are simpler (no reactive chemistry required) and favorable for shorter-duration depots (days to 1–2 weeks), while chemical hydrogels offer greater design flexibility for longer-duration depots (weeks to months) but require careful attention to the biocompatibility of the crosslinking chemistry and its reaction byproducts.

How do self-assembling peptide depots like Somatuline Depot work?

Somatuline® Depot (lanreotide acetate) employs a fundamentally different depot mechanism from PLGA microspheres. Lanreotide, a cyclic octapeptide somatostatin analog, self-assembles into nanotubes in aqueous solution—hollow cylindrical structures with the peptide arranged in β-sheet-like conformation, with hydrophobic residues oriented inward and hydrophilic residues outward. When injected subcutaneously as a concentrated aqueous suspension, these pre-formed nanotubes create a localized depot. Peptide release occurs not through polymer matrix degradation but through slow dissolution of the assembled nanotubes into soluble peptide monomers that enter the systemic circulation. The dissolution rate is governed by the nanotube stability (determined by intermolecular interactions within the assembly), the local peptide concentration gradient, and the injection site vascularity. This mechanism avoids the acidic microenvironment and reactive degradation products associated with PLGA, is manufactured without organic solvents, and achieves 28-day sustained release. The approach is peptide-specific—the peptide must have the intrinsic ability to self-assemble into stable nanostructures with appropriate dissolution kinetics—and has been most successfully applied to lanreotide, though related concepts are being investigated for other self-assembling therapeutic peptides.

What manufacturing challenges are unique to sterile PLGA microsphere depot products?

Sterile PLGA microsphere manufacturing presents a convergence of challenges. Terminal sterilization (gamma irradiation, ethylene oxide) can degrade both the polymer (molecular weight reduction accelerating peptide release) and the peptide (oxidation, aggregation), making aseptic manufacturing the standard approach. Aseptic manufacturing of multi-step processes (emulsion formation, solvent evaporation, microsphere collection, washing, drying, filling into vials) requires validated sterile processing for each step, with extensive environmental monitoring and process controls. The microsphere size distribution—a critical quality attribute determining release kinetics and syringeability—must be tightly controlled at commercial scale, typically through in-process sieving or classification. Residual solvent levels (dichloromethane, polyvinyl alcohol) must be reduced to regulatory limits (ICH Q3C) through validated drying processes. Lyophilization of the final product (if used) adds further complexity. The batch size must meet commercial demand while maintaining product quality attributes established during clinical development. These challenges contribute to the high manufacturing cost of PLGA microsphere products and have limited the number of approved products despite extensive academic research.

What is the role of peptide acylation in PLGA depot formulations?

Peptide acylation is a specific degradation pathway in PLGA delivery systems in which nucleophilic groups on the peptide—primarily the N-terminal amine and lysine side-chain amines—react with the electrophilic carbonyl carbons of PLGA ester bonds or with glycolic and lactic acid oligomers, forming covalent amide adducts. The reaction is favored by the acidic pH within the degrading microsphere (protonated nucleophiles are less reactive, but the high concentration and extended residence time compensate) and by the high effective concentration of reactive PLGA degradation products. Acylated peptide adducts typically have reduced or absent biological activity and altered physicochemical properties. The extent of acylation is peptide-specific (correlating with the number and accessibility of nucleophilic groups), microsphere-specific (correlating with the rate and extent of acid generation), and time-dependent (increasing over the depot duration). Acylation is a significant concern because it can progressively reduce the biologically active peptide content within the depot, potentially leading to declining therapeutic effect toward the end of the dosing interval.

How do oil-based peptide depots compare with PLGA microspheres?

Oil-based depots suspend the peptide (typically as a lipophilic salt or complex) in a biocompatible oil vehicle. The peptide dissolves slowly from the oil into the surrounding tissue fluid. Key differences from PLGA microspheres: oil-based depots are simpler to manufacture (mill/grind peptide in oil) and avoid PLGA degradation-related peptide stability issues (no acidic microclimate, no acylation), have a shorter regulatory pathway due to established oil vehicle precedents, and are generally suitable for shorter depot durations (days to 2–4 weeks vs. 1–6 months for PLGA). However, oil-based depots require the peptide to be formulated as a lipophilic salt with adequate oil dispersibility, may have less predictable release kinetics (dependent on oil viscosity, injection site, depot geometry), and can cause injection site reactions (oil granulomas). The choice between platforms depends on the peptide's properties, the desired release duration, manufacturing capabilities, and the target product profile. Researchers can access peptide characterization data including solubility and compatibility profiles through the RPL Peptide Data Center.

What are the key considerations for transitioning a peptide from daily injection to a depot formulation?

Key considerations include: Dose multiplication—a 1-month depot delivers roughly 30× the daily dose in a single administration, requiring acceptable safety margins at the resulting peak concentrations. Therapeutic index—the burst release component produces systemic concentrations that may exceed the therapeutic range for narrow-index peptides. Peptide stability—the peptide must survive 1–6 months in the depot environment (acidic pH for PLGA, elevated concentration, potential for aggregation and chemical degradation). Release profile—the depot release kinetics (typically triphasic for PLGA) must maintain therapeutic concentrations throughout the dosing interval without excessive peaks or subtherapeutic troughs. Injection volume and viscosity—practical limits on injection volume (typically <3–4 mL intramuscular, <1–2 mL subcutaneous) and needle gauge constrain the formulation. Manufacturing feasibility—the ability to produce sterile, reproducible depot product at commercial scale with acceptable cost of goods. And regulatory pathway—depot product development typically requires clinical demonstration of sustained efficacy and safety over the dosing interval, characterization of the release profile, and extensive chemistry, manufacturing, and controls (CMC) documentation. For peptide candidates at the depot feasibility stage, researchers can source high-purity reference materials and analytical support through [RPL Peptide](https://rplpeptides.com).

!!! info "" **About RPL Peptide:** [RPL Peptide](https://rplpeptides.com) is a supplier of high-purity research peptides with comprehensive analytical documentation including HPLC, LC-MS, and Certificates of Analysis (COA). For researchers developing injectable depot formulations requiring certified reference materials, visit [rplpeptides.com](https://rplpeptides.com) or explore detailed molecular data at the [RPL Peptide Data Center](https://data.rplpeptides.com).

What Is Established

  • Depot delivery is clinically validated for established peptide classes: LHRH agonists and somatostatin analogs are routinely administered on monthly to multi-month schedules via PLGA and related depots.
  • The release profile of PLGA depots is characteristically triphasic — burst, diffusion-controlled decline, erosion-accelerated terminal phase — and burst magnitude scales with loading and internal porosity.
  • Peptide stability inside degrading PLGA is the central formulation risk: acylation, deamidation, oxidation, and aggregation are documented pathways, mitigated but not eliminated by basic excipients such as magnesium hydroxide.

What Remains Uncertain

  • How closely in vitro release profiles predict in vivo behavior across patients and injection sites; the in situ solidification step adds variability that is poorly bounded.
  • Whether stabilization strategies generalize across peptides or must be re-derived per candidate — current evidence favors the latter.
  • Long-term local tolerability and tissue response beyond the observation windows of product-specific trials.

Research Gaps

  • Zero-order release from PLGA systems remains an aspiration rather than a routine capability; architectures that deliver it are still experimental.
  • Computational models linking polymer formulation parameters to human release profiles are under development and not yet validated as design standards.

Key References

  • Schwendeman SP, Shah RB, Bailey BA, Schwendeman AS (2014). Injectable controlled release depots for large molecules. Journal of Controlled Release 190:240–253. doi:10.1016/j.jconrel.2014.05.057 — Comprehensive review of depot platforms and the stability problems they must solve.
  • Fu K, Pack DW, Klibanov AM, Langer R (2000). Visual evidence of acidic environment within degrading poly(lactic-co-glycolic acid) (PLGA) microspheres. Pharmaceutical Research 17(1):100–106. doi:10.1023/A:1007582911958 — Direct measurement of the acidic microclimate that drives peptide degradation.
  • Johnson OL, Cleland JL, Lee HJ, et al. (1996). A month-long effect from a single injection of microencapsulated human growth hormone. Nature Medicine 2(7):795–799. doi:10.1038/nm0796-795 — Early demonstration that microencapsulated proteins can sustain month-scale exposure.
  • Zentner GM, Rathi R, Shih C, et al. (2001). Biodegradable block copolymers for delivery of proteins and water-insoluble drugs. Journal of Controlled Release 72(1–3):203–215. doi:10.1016/S0168-3659(01)00276-0 — The PLGA-PEG-PLGA thermogel (ReGel) foundation for aqueous depot processing.
  • van de Weert M, Hennink WE, Jiskoot W (2000). Protein instability in poly(lactic-co-glycolic acid) microparticles. Pharmaceutical Research 17(10):1159–1167. doi:10.1023/A:1026498209874 — Systematic account of destabilization mechanisms inside PLGA depots.
  • Peptide Stability Guide — practical background on degradation pathways relevant to depot microenvironments.
  • Stability FAQ — common questions on peptide degradation and stability testing for research peptides.

References

  1. Schwendeman SP, Shah RB, Bailey BA, Schwendeman AS. Injectable controlled release depots for large molecules. Journal of Controlled Release. 2014;190:240–253. doi:10.1016/j.jconrel.2014.05.057
  2. Jain R, Shah NH, Malick AW, Rhodes CT. Controlled drug delivery by biodegradable poly(ester) devices: different preparative approaches. Drug Development and Industrial Pharmacy. 1998;24(8):703–727. doi:10.3109/03639049809082719
  3. Mundargi RC, Babu VR, Rangaswamy V, Patel P, Aminabhavi TM. Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives. Journal of Controlled Release. 2008;125(3):193–209. doi:10.1016/j.jconrel.2007.09.013
  4. Dunn RL, English JP, Cowsar DR, Vanderbilt DD. Biodegradable in situ forming implants and methods of producing the same. US Patent 4,938,763. 1990.
  5. Packhaeuser CB, Schnieders J, Oster CG, Kissel T. In situ forming parenteral drug delivery systems: an overview. European Journal of Pharmaceutics and Biopharmaceutics. 2004;58(2):445–455. doi:10.1016/j.ejpb.2004.03.003
  6. Hatefi A, Amsden B. Biodegradable injectable in situ forming drug delivery systems. Journal of Controlled Release. 2002;80(1-3):9–28. doi:10.1016/S0168-3659(02)00008-1
  7. Yu L, Ding J. Injectable hydrogels as unique biomedical materials. Chemical Society Reviews. 2008;37(8):1473–1481. doi:10.1039/b800009k
  8. Valéry C, Artzner F, Paternostre M. Peptide nanotubes: molecular organisations, self-assembly mechanisms and application. Soft Matter. 2011;7(20):9583–9594. doi:10.1039/C1SM05698K
  9. Langer R. New methods of drug delivery. Science. 1990;249(4976):1527–1533. doi:10.1126/science.2218494
  10. Tracy MA, Ward KL, Firouzabadian L, et al. Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheres in vivo and in vitro. Biomaterials. 1999;20(11):1057–1062. doi:10.1016/S0142-9612(99)00005-8
  11. Fu K, Pack DW, Klibanov AM, Langer R. Visual evidence of acidic environment within degrading poly(lactic-co-glycolic acid) (PLGA) microspheres. Pharmaceutical Research. 2000;17(1):100–106. doi:10.1023/A:1007582911958
  12. van de Weert M, Hennink WE, Jiskoot W. Protein instability in poly(lactic-co-glycolic acid) microparticles. Pharmaceutical Research. 2000;17(10):1159–1167. doi:10.1023/A:1026498209874
  13. Zentner GM, Rathi R, Shih C, et al. Biodegradable block copolymers for delivery of proteins and water-insoluble drugs. Journal of Controlled Release. 2001;72(1-3):203–215. doi:10.1016/S0168-3659(01)00276-0
  14. Johnson OL, Cleland JL, Lee HJ, et al. A month-long effect from a single injection of microencapsulated human growth hormone. Nature Medicine. 1996;2(7):795–799. doi:10.1038/nm0796-795
  15. Wischke C, Schwendeman SP. Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles. International Journal of Pharmaceutics. 2008;364(2):298–327. doi:10.1016/j.ijpharm.2008.04.042

— Written by the RPL Scientific Editorial Team | Last updated August 2026

Related Articles: Nanoparticle-Based Peptide Delivery | Peptide Pharmacokinetics | Peptide Bioavailability Strategies | RPL Peptide | Peptide Research Data